Direct drop of 40,000 yuan 257 kinds of consumables the lowest price in the country announced

September 8th, Heilongjiang Public Resources Trading Network released the "Public Notice on Adjusting the Price Information of High-Value Medical Supplies" and announced the results of the price reduction of 257 kinds of consumables.According to Cypress Blue equipment combing, this high-value supplies price adjustment involves electrophysiology, non-vascular implants, joints, oral, neurosurgery, in vitro circulation and blood purification, vascular intervention and other consumables, involving Belang Medical, Poco, Fesenjus, Shanghai minimally invasive, Xeronic and other well-known domestic and foreign equipment products.Among them, the maximum price reduction of 54.55 percent, there are 8 kinds of consumables price reduction in more than 50%, 6 kinds of consumables price reduction between 40%-50%, 14 kinds of consumables price reduction between 30%-40%, 16 kinds of consumables price reduction between 20%-30%.Such as a skull fixed titanium mesh and screw system, the price from 6600 yuan to 3000 yuan, a decrease of 54.55%;Tianjin Saning Bioengineering Technology Co., Ltd., a collagen base bone Repair materials, the price from 5600 yuan to 2800 yuan, a 50% decline,drug-controlled artificial crystals from 3,500 yuan to 2,292.99 yuan, a decline of 34.49%.Although some consumables did not fall the most, the absolute value of the price reduction exceeded 40,000 yuan. Poco's implantable pacemaker, the price fell from 93,060 yuan to 52,380 yuan, a price reduction of 40,680 yuan, a drop of 43.71 percent.This decline has been close to or even exceeded the average decline in strip purchases in some provinces.On August 19 this year, Anhui Provincial Health Insurance Bureau announced the completion of the province's public medical institutions, the second batch of high-value medical supplies centralized belt procurement bargaining, of which 82 products in the pacemaker category fell by an average of 46.75 percent.On July 31, 2019, the results of the first consumables alliance negotiations in Jiangsu Province were announced, in which pacemakers were negotiated by production enterprises, with an average decrease of 15.86 percent and a maximum decrease of 38.13 percent.

multinational arms companies dominate hundreds of billions ofIt is understood that the pacemaker is an electronic treatment device implanted into the body, through the pulse generator to distribute the energy provided by the battery electrical impulses, through the conduction of wire electrodes, stimulate the electrodes contact with the heart muscle, so that the heart agitation and contraction, so as to achieve the treatment of certain arrhythmic disorders caused by arrhythmic arrhythmic disorders.The market for electrophysiology and pacemakers is not to be underestimated, with global cardiac rhythm management expected to reach about $14.3 billion in 2018 and $15.7 billion ($107.8 billion) in 2020, with a compound annual growth rate of 4.6%, according to GlobalData.Pacemakers are divided into single-cavity pacemakers, two-chamber pacemakers, three-cavity pacemakers and three-chamber defibrillator pacemakers.China Industry Information Network data show that single-cavity pacemakers for low-end products, domestic prices in 2-3 million yuan, limited efficacy, can maintain the basic needs of patients, but may trigger pacemaker syndromeThree-cavity pacemaker is the most high-end product, the domestic price of about 100,000 yuan, can treat left and right heart chamber out of pace caused by heart failure, three-cavity defibrillator is a combination of three-cavity pacemaker and defibrillator, for dilated cardiomyopathy patients have significant efficacy, but the highest price, reached 15-25 million yuan.According to the 2015 China Cardiovascular Report, bi-cavity pacemakers account for nearly 67% of all types of pacemakers.   The domestic market penetration rate is low and multinational arms companies occupy the main market, China Industrial Information Network data show that by 2017, Medtron, St. Jude, Boston Scientific brand occupies more than 80% of the market share.   It is understood that pacemaker research and development technical barriers are high, until 2009, domestic enterprises only broke the pacemaker's foreign monopoly.   Firestone creation combing shows that Shaanxi Qinming Medical Instruments Co., Ltd. is China's first professional pacemaker business enterprises, in July 2009, it and Xi'an 2312S/M implantable pacemaker developed in cooperation for 6 years successfully obtained a medical device registration certificate, breaking the domestic pacemaker market foreign monopoly.   In 2010 and 2012, Lepu Medical acquired a total of 75.1% of Qin Ming Medical's shares, becoming the controlling shareholder of QinMing Medical, and in 2016, Qinming Medical officially changed its name to Lepu Medical Electronic Instruments Co., Ltd. (Cypress Blue Equipment
)